14.10

2.04% 0.1206

Zevra Therapeutics Inc (ZVRA)

Overview News Price History Option Chain Discussions Forecast Stock Split

Zevra Therapeutics Inc stock is traded at $14.10, with a volume of 78,243. It is up +2.04% in the last 24 hours and up +34.45% over the past month. Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.

Previous Close:

$13.98

Open:

$13.99

24h Volume:

78,243

Relative Volume:

0.05

Market Cap:

$832.15M

Revenue:

$122.29M

Net Income/Loss:

$122.31M

P/E Ratio:

6.5465

EPS:

2.1539

Net Cash Flow:

$12.00M

1W Performance:

+1.82%

1M Performance:

+34.45%

6M Performance:

+71.66%

1Y Performance:

+46.46%

1-Day Range:

$13.99

$14.37

1-Week Range:

$13.53

$14.58

52-Week Range:

$7.16

$14.58

Zevra Therapeutics Inc Stock (ZVRA) Company Profile

Name

Zevra Therapeutics Inc

Sector

Healthcare (1097)

Industry

Biotechnology (615)

Phone

(888) 958-1253

Address

101 FEDERAL STREET, BOSTON

Employee

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

ZVRA's Discussions on Twitter

Compare ZVRA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ZVRA Zevra Therapeutics Inc	14.08	847.71M	122.29M	122.31M	12.00M	2.1539
VRTX Vertex Pharmaceuticals Inc	516.15	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	640.97	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	921.99	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	309.59	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	191.26	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-16-26	Initiated	BTIG Research	Buy
Jul-02-25	Initiated	H.C. Wainwright	Buy
Jan-08-25	Resumed	Cantor Fitzgerald	Overweight
Oct-07-24	Initiated	Guggenheim	Buy
Sep-24-24	Initiated	JMP Securities	Mkt Outperform
Sep-24-24	Reiterated	Maxim Group	Buy
Apr-02-24	Reiterated	Maxim Group	Buy
Mar-12-24	Initiated	William Blair	Outperform
Mar-17-23	Initiated	Maxim Group	Buy

View All

Zevra Therapeutics Inc Stock (ZVRA) Latest News

Jul 01, 2026

(ZVRA) Risk Channels and Responsive Allocation - Stock Traders Daily

Jul 01, 2026

ZVRAZevra Therapeutics Inc Latest SEC Filings - Finviz

Jul 01, 2026

Jun 29, 2026

Enterprise value to revenue forward of Zevra Therapeutics, Inc. – NASDAQ:ZVRA - TradingView

Jun 29, 2026

Zevra Therapeutics, Inc.(NasdaqGS: ZVRA) added to Russell 2000 Value Benchmark - marketscreener.com

Jun 29, 2026

Zevra Therapeutics, Inc.(NasdaqGS:ZVRA) added to Russell Microcap Value Benchmark Index - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Zevra Therapeutics, Inc.(NasdaqGS: ZVRA) added to Russell 2000 Value-Defensive Index - marketscreener.com

Jun 28, 2026

Zevra Therapeutics, Inc.(NasdaqGS: ZVRA) added to Russell 2000 Growth-Defensive Index - marketscreener.com

Jun 28, 2026

Price to book forward of Zevra Therapeutics, Inc. – DUS:1GDA - TradingView

Jun 28, 2026

Zevra Therapeutics, Inc.(NasdaqGS: ZVRA) added to Russell 2000 Defensive Index - marketscreener.com

Jun 28, 2026

Price to sales forward of Zevra Therapeutics, Inc. – NASDAQ:ZVRA - TradingView

Jun 28, 2026

Price to sales forward of Zevra Therapeutics, Inc. – DUS:1GDA - TradingView

Jun 28, 2026

Enterprise value to EBIT forward of Zevra Therapeutics, Inc. – NASDAQ:ZVRA - TradingView

Jun 28, 2026

Enterprise value to EBITDA forward of Zevra Therapeutics, Inc. – DUS:1GDA - TradingView

Jun 28, 2026

Jun 27, 2026

H.C. Wainwright reiterates Zevra Therapeutics stock rating on infant study data - Investing.com Nigeria

Jun 24, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jun 24, 2026

Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC) - Sahm

Jun 24, 2026

Jun 23, 2026

Zevra Therapeutics chief legal & compliance sells $438,303 in stock By Investing.com - Investing.com South Africa

Jun 23, 2026

Form 4 Zevra Therapeutics Inc For: 23 June By Investing.com - Investing.com South Africa

Jun 23, 2026

ZVRA: Zevra Therapeutics Releases Positive Findings on Arimoclom - GuruFocus

Jun 23, 2026

Zevra Therapeutics chief legal & compliance sells $438,303 in stock - Investing.com

Jun 23, 2026

Zevra Therapeutics (ZVRA) legal chief sells shares after RSU exercise - Stock Titan

Jun 23, 2026

ZVRA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $26 - GuruFocus

Jun 23, 2026

Zevra Therapeutics reports positive MIPLYFFA pediatric data - grafa.com

Jun 23, 2026

H.C. Wainwright Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $26 - Moomoo

Jun 23, 2026

Jun 20, 2026

(ZVRA) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Jun 20, 2026

Jun 19, 2026

Alicia Secor Takes A Bullish Stance, Acquiring $51K Worth Of Zevra Therapeutics Stock Options - Benzinga

Jun 19, 2026

Jun 18, 2026

Director at Zevra Therapeutics (ZVRA) granted 30,000 stock options - Stock Titan

Jun 18, 2026

Zevra Therapeutics (ZVRA) director awarded 30,000 options at $11.17 strike - Stock Titan

Jun 18, 2026

Board member at Zevra (NASDAQ: ZVRA) receives 30,000-share option grant - Stock Titan

Jun 18, 2026

Zevra Therapeutics (ZVRA) awards director 30,000 stock options - Stock Titan

Jun 18, 2026

Zevra Therapeutics (NASDAQ: ZVRA) director gets 30,000 stock options grant - Stock Titan

Jun 18, 2026

Zevra Therapeutics (ZVRA) director awarded 30,000 stock options at set price - Stock Titan

Jun 18, 2026